Drug
Antibody-Drug Conjugates
Antibody-Drug Conjugates is a pharmaceutical drug with 3 clinical trials. Historical success rate of 100.0%.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 2 completed trials
Completion Rate
100%(2/2)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_2
2
67%
Phase Distribution
0
Early Stage
2
Mid Stage
0
Late Stage
Phase Distribution2 total trials
Phase 2Efficacy & side effects
2(100.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
100.0%
2 of 2 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
3
all time
Status Distribution
Active(1)
Completed(2)
Detailed Status
Completed2
Not yet recruiting1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
0
Success Rate
100.0%
Most Advanced
Phase 2
Trials by Phase
Phase 22 (100.0%)
Trials by Status
completed267%
not_yet_recruiting133%
Recent Activity
0 active trials
Showing 3 of 3
not_yet_recruitingphase_2
SCALp Cooling for pReventing aLopecia With nEw anTibody-drug Conjugates
NCT07474558
completed
Safety and Efficacy Real-world Data of Trastuzumab Deruxtecan and Sacituzumab Govitecan
NCT06504719
completedphase_2
Study of Palbociclib and Trastuzumab With Endocrine Therapy in HER2-positive Metastatic Breast Cancer
NCT02448420
Clinical Trials (3)
Showing 3 of 3 trials
NCT07474558Phase 2
SCALp Cooling for pReventing aLopecia With nEw anTibody-drug Conjugates
NCT06504719
Safety and Efficacy Real-world Data of Trastuzumab Deruxtecan and Sacituzumab Govitecan
NCT02448420Phase 2
Study of Palbociclib and Trastuzumab With Endocrine Therapy in HER2-positive Metastatic Breast Cancer
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3